The FDA regulates compounding peptides by placing them into specific categories. Category 1 peptides are substances currently under evaluation that can generally be compounded by licensed pharmacies. Category 2 peptides are substances the FDA has identified as presenting significant safety risks, meaning they are prohibited from being compounded for human use. Understanding this distinction is essential for any clinic operating in the peptide therapeutics space.[4]
Understanding the FDA Compounding Framework
The FDA regulates bulk drug substances used in compounding under Section 503A of the Food, Drug, and Cosmetic Act, requiring substances to be explicitly listed or categorized before they can be legally compounded.
For peptide clinics and compounding pharmacies, regulatory compliance is the foundation of operational stability. The Food and Drug Administration does not evaluate all peptides equally. Instead, the agency evaluates bulk drug substances to determine whether they are appropriate for use in compounding. If a peptide is not a component of an FDA-approved drug or the subject of a United States Pharmacopeia (USP) monograph, it must be evaluated for inclusion on the "503A Bulks List."
During this evaluation process, the FDA places nominated substances into specific categories. These categories dictate whether a pharmacy can legally compound the substance and, consequently, whether a clinic can legally prescribe and sell it. The category system is not static. The FDA continuously reviews substances as new clinical data becomes available, meaning a peptide's status can change.
What Are Category 1 Peptides?
Category 1 peptides are bulk drug substances nominated for inclusion on the 503A bulks list that are currently under evaluation and do not present significant safety risks.
When a substance is placed in Category 1, it means the FDA has received sufficient information to evaluate it, and the agency has not identified any significant safety risks during its preliminary review. Under current FDA policy, the agency generally does not intend to take regulatory action against a licensed pharmacy that compounds a drug using a Category 1 substance, provided the pharmacy meets all other conditions of Section 503A.
For peptide clinics, Category 1 represents the compliant path forward. Prescribing and dispensing Category 1 peptides through a licensed compounding pharmacy aligns with regulatory expectations[1] and allows the business to operate transparently. Examples of peptides that remained in Category 1 as of early 2026 include BPC-157 (under continued review) and certain semaglutide formulations during shortage periods.
The payment infrastructure that supports compliant Category 1 peptide sales also matters. Understanding what a BIN is and why owning one matters gives peptide businesses a significant advantage in account stability.
"Category 1 represents the compliant path forward. Operating within this framework is what allows a clinic to build a stable, scalable business."
What Are Category 2 Peptides?
Category 2 peptides are substances the FDA has evaluated and identified as presenting significant safety risks, meaning they cannot be legally compounded.
The designation of Category 2 is a clear regulatory boundary. When the FDA places a substance in this category, it is stating that the substance should not be used in compounding.[2] Pharmacies that compound Category 2 peptides expose themselves to immediate regulatory action, including warning letters and potential shutdown.
The 2023 and 2024 Reclassifications
The landscape shifted dramatically in late 2023 when the FDA moved 19 popular peptides from Category 1 to Category 2. This list included highly sought-after compounds such as CJC-1295, Ipamorelin, AOD-9604, and Thymosin Alpha-1. The agency cited safety concerns and a lack of sufficient clinical data to support their continued use in compounding.
While the Pharmacy Compounding Advisory Committee (PCAC) continues to review some of these substances, they remain in Category 2 as of early 2026, meaning they are prohibited from being compounded for human use.[2] Clinics that had built their protocols around these compounds were forced to restructure their offerings entirely.
The "Research Use Only" Loophole and Its Risks
Selling Category 2 peptides under "Research Use Only" labels while implying human use is considered misbranding by the FDA and exposes the vendor to severe regulatory and financial penalties.
In response to the Category 2 reclassifications, a parallel market expanded where vendors sell these prohibited peptides labeled "For Research Use Only" (RUO) and "Not for Human Consumption." While this labeling attempts to circumvent FDA compounding rules, the agency evaluates the totality of a vendor's operations.
If a website's imagery, customer base, dosage instructions, or implied messaging suggests the peptides are intended for human use, the FDA considers this misbranding and the sale of unapproved new drugs. Operating in this gray area is highly unstable and frequently results in regulatory enforcement, card network violations, and payment processor terminations.
"The FDA evaluates the totality of your operations. Labeling alone does not determine compliance. Your entire marketing posture does."
How Classification Affects Payment Processing
Standard processors use algorithmic bans to terminate all peptide accounts, while specialized processors evaluate your compliance with Category 1 regulations to provide stable infrastructure.
The distinction between Category 1 and Category 2 is not just a clinical concern. It is a critical factor in your ability to process payments. Standard payment processors like Stripe and Square do not distinguish between the categories. Their automated algorithms simply flag the word "peptide" and terminate the account, treating all peptide sales as restricted pharmaceuticals regardless of compliance status.
Furthermore, attempting to process payments for Category 2 peptides, even under the guise of “Research Use Only,” violates the strict rules set by card networks like Visa and Mastercard regarding restricted substances.
Scroll right to see full table
| Factor | Category 1 Peptides | Category 2 Peptides |
|---|---|---|
| FDA Status | Under evaluation | Identified safety risks |
| Compounding | Generally permitted (503A) | Prohibited |
| Regulatory Risk | Low (if 503A compliant) | High |
| Standard Processor (Stripe) | Algorithmic termination | Algorithmic termination |
| Specialized Processor (DIVIOR) | Approved with manual underwriting | Declined (card network rules) |
At DIVIOR, our underwriting team understands the FDA compounding framework. Because we own our Bank Identification Number, we do not rely on the blanket algorithmic bans used by standard aggregators. We evaluate your clinic based on its actual compliance posture. If you are operating compliantly within the Category 1 framework, we provide the institutional-grade payment infrastructure required to scale your business without the constant threat of sudden account termination.